Colle Capital

Colle Capital is a global, opportunistic, early-stage technology venture fund that strategically invests in innovative companies. The firm is characterized by its emphasis on data-driven decision-making, investing in visionary individuals, fostering bold ideas, and promoting agility in execution. While maintaining an opportunistic approach, Colle Capital frequently gravitates towards investments in the Logistics, Healthcare, and FinTech sectors, recognizing the intrinsic value of data in these areas.

Founded in 2015, Colle Capital Partners was established by founding partner Victoria Grace. The firm's name is inspired by the Colle System, a chess opening strategy known for its solid development and deceptive sting, reflecting the firm's methodical yet impactful investment philosophy. Colle Capital prefers to engage early in a company's lifecycle, providing critical support to help young startups achieve their objectives. The firm is committed to identifying and backing teams that demonstrate not only intellect and passion but also agility in their thinking and execution, with a clear focus on sustainability across business practices, unit economics, and environmental impact.

Colle Capital boasts a diverse portfolio of companies across various technology verticals. Notable investments include FBN, an AI-powered platform for family farms; Dandelion Health, which accelerates clinical development using AI and real-world patient data; Instnt, a solution for turning identity fraud losses into an insurable asset; and Hyperfine, developer of the world’s first point-of-care MRI system. The firm has also seen several portfolio companies acquired, such as Apriso (acquired by Dassault Systèmes), Metastorm (acquired by OpenText), and Syft (acquired by Indeed).

The firm's leadership team includes Founding Partner Victoria Grace, who brings extensive experience in originating, structuring, and monitoring venture capital transactions across a broad range of industries, including enterprise B2B software, medical devices, health IT, FinTech, hardware, virtual reality, and D2C retail. She is particularly passionate about companies with a strong ESG focus. Alessandro Arlotti serves as an Investment Team Member, contributing to sourcing, evaluating, and supporting early-stage investments, while Dr. Cheryl Martin acts as a Venture Partner, leveraging her expertise in designing and implementing solutions for complex problems in both public and private sectors.